PubMed:32412509
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 1163-1171 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T2 | 1451-1460 | Body_part | denotes | cytokines | http://purl.org/sig/ont/fma/fma84050 |
| T3 | 1491-1504 | Body_part | denotes | interleukin 6 | http://purl.org/sig/ont/fma/fma264829 |
| T4 | 1491-1502 | Body_part | denotes | interleukin | http://purl.org/sig/ont/fma/fma86578 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 0-8 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T2 | 30-34 | Disease | denotes | AIDS | http://purl.obolibrary.org/obo/MONDO_0012268 |
| T3 | 72-119 | Disease | denotes | severe acute respiratory syndrome coronavirus 2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T4 | 72-105 | Disease | denotes | severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T5 | 121-129 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T6 | 231-235 | Disease | denotes | AIDS | http://purl.obolibrary.org/obo/MONDO_0012268 |
| T7 | 382-392 | Disease | denotes | (COVID)-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T8 | 540-548 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T9 | 551-561 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T10 | 614-622 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T11 | 749-757 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T12 | 760-769 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T13 | 894-902 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T14 | 905-914 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T15 | 1224-1232 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T16 | 1233-1242 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
| T17 | 1632-1640 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 133-136 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T2 | 270-277 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T3 | 405-408 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T4 | 513-520 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T5 | 524-530 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | active |
| T6 | 607-612 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tests |
| T7 | 686-687 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T8 | 945-951 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
| T9 | 1112-1115 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T10 | 1491-1504 | http://purl.obolibrary.org/obo/PR_000001393 | denotes | interleukin 6 |
| T11 | 1565-1566 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 924-934 | Chemical | denotes | antivirals | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T2 | 974-984 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
| T3 | 1038-1057 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
| T4 | 1038-1047 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T5 | 1048-1057 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T6 | 1275-1298 | Chemical | denotes | antiinflammatory agents | http://purl.obolibrary.org/obo/CHEBI_67079 |
| T7 | 1354-1372 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T8 | 1470-1481 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 1163-1177 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
| T2 | 1233-1242 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
| T3 | 1253-1273 | Phenotype | denotes | respiratory distress | http://purl.obolibrary.org/obo/HP_0002098 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2 | 0-8 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 3 | 30-34 | Disease | denotes | AIDS | MESH:D000163 |
| 23 | 72-119 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | Tax:2697049 |
| 24 | 121-131 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 25 | 231-235 | Disease | denotes | AIDS | MESH:D000163 |
| 26 | 362-381 | Disease | denotes | Coronavirus Disease | MESH:D018352 |
| 27 | 383-388 | Disease | denotes | COVID | MESH:C000657245 |
| 28 | 540-561 | Disease | denotes | SARS-CoV-2 infections | MESH:C000657245 |
| 29 | 614-622 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 30 | 623-629 | Disease | denotes | deaths | MESH:D003643 |
| 31 | 754-769 | Disease | denotes | CoV-2 infection | MESH:C000657245 |
| 32 | 894-914 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
| 33 | 974-984 | Chemical | denotes | remdesivir | MESH:C000606551 |
| 34 | 1038-1057 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
| 35 | 1224-1242 | Disease | denotes | COVID-19 pneumonia | MESH:C000657245 |
| 36 | 1247-1273 | Disease | denotes | acute respiratory distress | MESH:D012128 |
| 37 | 1338-1352 | Chemical | denotes | orticosteroids | |
| 38 | 1354-1372 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 39 | 1470-1481 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 40 | 1491-1504 | Gene | denotes | interleukin 6 | Gene:3569 |
| 41 | 1632-1640 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-48 | Sentence | denotes | COVID-19 Comes 40 Years After AIDS - Any Lesson? |
| T2 | 49-202 | Sentence | denotes | The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. |
| T3 | 203-356 | Sentence | denotes | In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. |
| T4 | 357-501 | Sentence | denotes | With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. |
| T5 | 502-613 | Sentence | denotes | Diagnostic testing of active and past SARS-CoV-2 infections needs to expand rapidly, ideally using rapid tests. |
| T6 | 614-770 | Sentence | denotes | COVID-19 deaths are highly concentrated in the elderly population, with a large proportion of fatalities being "with" rather than "by" SARS-CoV-2 infection. |
| T7 | 771-851 | Sentence | denotes | They are often the result of inadequate health care due to overwhelming demands. |
| T8 | 852-915 | Sentence | denotes | To date, there is no specific therapy for SARS-CoV-2 infection. |
| T9 | 916-1018 | Sentence | denotes | Several antivirals are being tested clinically, including remdesivir, at this time the most promising. |
| T10 | 1019-1127 | Sentence | denotes | For others such as lopinavir/ritonavir, neither significant virological nor clinical benefit has been shown. |
| T11 | 1128-1322 | Sentence | denotes | Given the characteristic pulmonary cytokine storm underlying the pathogenic mechanism of severe COVID-19 pneumonia and acute respiratory distress, antiinflammatory agents are being investigated. |
| T12 | 1323-1391 | Sentence | denotes | The benefit of orticosteroids, hydroxychloroquine, etc., is limited. |
| T13 | 1392-1553 | Sentence | denotes | Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. |
| T14 | 1554-1650 | Sentence | denotes | Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic. |
LitCovid-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-8 | SP_7 | denotes | COVID-19 |
| T2 | 72-84 | SP_7 | denotes | severe acute |
| T3 | 85-96 | SP_7;UBERON:0001004 | denotes | respiratory |
| T4 | 97-119 | SP_7 | denotes | syndrome coronavirus 2 |
| T5 | 121-131 | SP_7 | denotes | SARS-CoV-2 |
| T6 | 362-373 | NCBITaxon:11118 | denotes | Coronavirus |
| T7 | 540-550 | SP_7 | denotes | SARS-CoV-2 |
| T8 | 614-622 | SP_7 | denotes | COVID-19 |
| T9 | 623-629 | GO:0016265 | denotes | deaths |
| T10 | 749-759 | SP_7 | denotes | SARS-CoV-2 |
| T11 | 894-904 | SP_7 | denotes | SARS-CoV-2 |
| T12 | 974-984 | DG_28 | denotes | remdesivir |
| T13 | 1038-1047 | DG_23 | denotes | lopinavir |
| T14 | 1048-1057 | DG_30 | denotes | ritonavir |
| T15 | 1153-1162 | UBERON:0002048 | denotes | pulmonary |
| T16 | 1224-1232 | SP_7 | denotes | COVID-19 |
| T17 | 1253-1264 | UBERON:0001004 | denotes | respiratory |
| T18 | 1292-1298 | CHEBI:67079;CHEBI:67079 | denotes | agents |
| T19 | 1354-1372 | CHEBI:5801;DG_20;CHEBI:5801 | denotes | hydroxychloroquine |
| T20 | 1403-1413 | GO:0042571 | denotes | antibodies |
| T21 | 1470-1481 | DG_35 | denotes | tocilizumab |
| T22 | 1491-1504 | PR:000001393 | denotes | interleukin 6 |
| T23 | 1616-1627 | GO:0065007 | denotes | controlling |
| T24 | 1632-1640 | SP_7 | denotes | COVID-19 |
hydroxychloroquine
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 1163-1177 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
| T2 | 1233-1242 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
| T3 | 1253-1273 | Phenotype | denotes | respiratory distress | http://purl.obolibrary.org/obo/HP_0002098 |
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-48 | Sentence | denotes | COVID-19 Comes 40 Years After AIDS - Any Lesson? |
| T2 | 49-202 | Sentence | denotes | The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. |
| T3 | 203-356 | Sentence | denotes | In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. |
| T4 | 357-501 | Sentence | denotes | With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. |
| T5 | 502-613 | Sentence | denotes | Diagnostic testing of active and past SARS-CoV-2 infections needs to expand rapidly, ideally using rapid tests. |
| T6 | 614-770 | Sentence | denotes | COVID-19 deaths are highly concentrated in the elderly population, with a large proportion of fatalities being "with" rather than "by" SARS-CoV-2 infection. |
| T7 | 771-851 | Sentence | denotes | They are often the result of inadequate health care due to overwhelming demands. |
| T8 | 852-915 | Sentence | denotes | To date, there is no specific therapy for SARS-CoV-2 infection. |
| T9 | 916-1018 | Sentence | denotes | Several antivirals are being tested clinically, including remdesivir, at this time the most promising. |
| T10 | 1019-1127 | Sentence | denotes | For others such as lopinavir/ritonavir, neither significant virological nor clinical benefit has been shown. |
| T11 | 1128-1322 | Sentence | denotes | Given the characteristic pulmonary cytokine storm underlying the pathogenic mechanism of severe COVID-19 pneumonia and acute respiratory distress, antiinflammatory agents are being investigated. |
| T12 | 1323-1391 | Sentence | denotes | The benefit of orticosteroids, hydroxychloroquine, etc., is limited. |
| T13 | 1392-1553 | Sentence | denotes | Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. |
| T14 | 1554-1650 | Sentence | denotes | Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic. |
| T1 | 0-48 | Sentence | denotes | COVID-19 Comes 40 Years After AIDS - Any Lesson? |
| T2 | 49-202 | Sentence | denotes | The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. |
| T3 | 203-356 | Sentence | denotes | In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. |
| T4 | 357-501 | Sentence | denotes | With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. |
| T5 | 502-613 | Sentence | denotes | Diagnostic testing of active and past SARS-CoV-2 infections needs to expand rapidly, ideally using rapid tests. |
| T6 | 614-770 | Sentence | denotes | COVID-19 deaths are highly concentrated in the elderly population, with a large proportion of fatalities being "with" rather than "by" SARS-CoV-2 infection. |
| T7 | 771-851 | Sentence | denotes | They are often the result of inadequate health care due to overwhelming demands. |
| T8 | 852-915 | Sentence | denotes | To date, there is no specific therapy for SARS-CoV-2 infection. |
| T9 | 916-1018 | Sentence | denotes | Several antivirals are being tested clinically, including remdesivir, at this time the most promising. |
| T10 | 1019-1127 | Sentence | denotes | For others such as lopinavir/ritonavir, neither significant virological nor clinical benefit has been shown. |
| T11 | 1128-1322 | Sentence | denotes | Given the characteristic pulmonary cytokine storm underlying the pathogenic mechanism of severe COVID-19 pneumonia and acute respiratory distress, antiinflammatory agents are being investigated. |
| T12 | 1323-1391 | Sentence | denotes | The benefit of orticosteroids, hydroxychloroquine, etc., is limited. |
| T13 | 1392-1553 | Sentence | denotes | Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. |
| T14 | 1554-1650 | Sentence | denotes | Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic. |